Food Science & Nutrition · 8 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review summarizes preclinical evidence on mangiferin's anticancer effects across various models, finding it inhibits tumor growth and angiogenesis while increasing apoptosis. However, the review concludes that mangiferin has low bioavailability and that human clinical trials are needed.
This narrative review synthesizes preclinical data from in vitro (human cell lines) and in vivo (mice, hamsters) studies on mangiferin's anticancer effects. The authors report that mangiferin demonstrates therapeutic potential against multiple cancers by targeting enzymes, signaling pathways, and apoptotic proteins, thereby inhibiting tumor growth, angiogenesis, and metastasis. The review highlights that mangiferin is safe with fewer side effects on normal cells but has low water solubility and poor bioavailability. Techniques like nanoparticle formulation and combination with other drugs are noted to enhance bioavailability and therapeutic efficacy. The primary limitation acknowledged is that all evidence is preclinical, with no human trial data available, making clinical application premature. The review calls for further research to determine effective dosing and to evaluate its safety and efficacy in humans.
